Drug Type Fab fragment, Biosimilar |
Synonyms Ranibizumab biosimilar, 重组抗VEGF人源化单克隆抗体Fab(齐鲁制药), BCD 300 + [4] |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (15 Dec 2023), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Choroidal Neovascularization | EU | 15 Jan 2024 | |
Choroidal Neovascularization | IS | 15 Jan 2024 | |
Choroidal Neovascularization | LI | 15 Jan 2024 | |
Choroidal Neovascularization | NO | 15 Jan 2024 | |
Diabetic macular oedema | EU | 15 Jan 2024 | |
Diabetic macular oedema | IS | 15 Jan 2024 | |
Diabetic macular oedema | LI | 15 Jan 2024 | |
Diabetic macular oedema | NO | 15 Jan 2024 | |
Proliferative retinopathy with diabetes mellitus | EU | 15 Jan 2024 | |
Proliferative retinopathy with diabetes mellitus | IS | 15 Jan 2024 | |
Proliferative retinopathy with diabetes mellitus | LI | 15 Jan 2024 | |
Proliferative retinopathy with diabetes mellitus | NO | 15 Jan 2024 | |
Wet age-related macular degeneration | EU | 15 Jan 2024 | |
Wet age-related macular degeneration | IS | 15 Jan 2024 | |
Wet age-related macular degeneration | LI | 15 Jan 2024 | |
Wet age-related macular degeneration | NO | 15 Jan 2024 | |
Retinal vein occlusion-related macular edema | EU | 15 Dec 2023 | |
Retinal vein occlusion-related macular edema | IS | 15 Dec 2023 | |
Retinal vein occlusion-related macular edema | LI | 15 Dec 2023 | |
Retinal vein occlusion-related macular edema | NO | 15 Dec 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dystrophy, Macular | NDA/BLA | CN | 29 Jan 2023 | |
Wet Macular Degeneration | Phase 1 | CN | 20 Dec 2017 | |
Colorectal Cancer | Phase 1 | CN | 21 Mar 2016 | |
Non-Small Cell Lung Cancer | Phase 1 | CN | 21 Mar 2016 |